Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/18/2013

Company Name Symbol %Change
STAAR SURGIC STAA
10.98%
DTS INC DTSI
6.89%
ANIKA THERAP ANIK
6.04%
LUMOS NETWOR LMOS
5.70%
INSTEEL IND IIIN
5.28%

Owens & Minor Closes Movianto Buy

by Zacks Equity Research

September 06, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Owens & Minor, Inc. (OMI - Snapshot Report), leading supplier of healthcare products, recently completed its earlier announced acquisition of the majority of Movianto Group. Movianto is the European healthcare third-party logistics (3PL) business of Celesio AG, a global provider of logistics in the healthcare sector.

Owens & Minor purchased Movianto Group from Celesio AG for roughly $158 million (€130 million). The company financed the acquisition with its available cash. It exited the second quarter with cash and cash equivalents of $224.9 million, up 41.3% year over year.

While the buyout is expected to be dilutive to Owens & Minor’s earnings per share in 2012, it is envisaged to be accretive from 2014 onwards. The acquisition also presents a feasible route to enter the European market.

Movianto operates from 23 logistics centers in 11 European nations. With a strength of 1,800 employees, the company renders warehousing, transportation and cold chain logistics along with value-added services like order-to-cash, repackaging and relabeling of products. Thus, the acquisition will enable Owens & Minor to serve a wider customer base of pharmaceutical and medical device manufacturers.

Owens & Minor is expected to make use of Movianto’s operational capabilities and diversify its service channels. The acquisition will also allow the company to expand its foothold in the global market, helped by the complementary services of Movianto.

Per management, the acquisition has enhanced the scale and scope of Owens & Minor's business in the field of third party logistics. The company looks forward to lending assistance to its manufacturing partners on an international platform through third party logistic solutions.

Headquartered in Richmond, Virginia, Owens & Minor is a Fortune 500 company which administers healthcare supply-chain management solutions. The company continues to venture into new markets and expand its core business processes. With strong business fundamentals and foothold expansion in the European market, it is well-positioned to accelerate growth in the years ahead.

However, Owens & Minor continue to rely on select customers for a major share of its revenues. It also depends on group purchasing organizations to seek significant contracts. Additionally, the company faces a tough competitive landscape with Cardinal Health (CAH - Analyst Report) and McKesson Corporation (MCK - Analyst Report).

Owens & Minor currently holds a Zacks #4 Rank, which translates into a short-term Sell rating.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.